Menu
Search
|

Menu

Close
X

Radius Health Inc RDUS.OQ (NASDAQ Stock Exchange Global Market)

37.91 USD
-0.66 (-1.71%)
As of Feb 16
chart
Previous Close 38.57
Open 38.67
Volume 156,581
3m Avg Volume 308,026
Today’s High 38.67
Today’s Low 37.50
52 Week High 49.15
52 Week Low 24.68
Shares Outstanding (mil) 44.59
Market Capitalization (mil) 1,690.48
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.38 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
14
FY16
0
FY15
0
EPS (USD)
FY17
-4.210
FY16
-4.244
FY15
-2.533
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
117.00
8.57
Price to Book (MRQ)
vs sector
5.52
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
53.22
15.12
LT Debt to Equity (MRQ)
vs sector
53.22
11.85
Return on Investment (TTM)
vs sector
-57.43
13.54
Return on Equity (TTM)
vs sector
-71.69
14.80

EXECUTIVE LEADERSHIP

Kurt Graves
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Jesper Hoiland
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Jose Carmona
Chief Financial Officer, Principal Accounting Officer, Treasurer, Since 2017
Salary: --
Bonus: --
Gary Hattersley
Senior Vice President, Chief Scientific Officer, Since 2014
Salary: $300,936.00
Bonus: $180,000.00
Brent Hatzis-Schoch
Senior Vice President, General Counsel, Secretary, Since 2017
Salary: $279,718.00
Bonus: $160,938.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

950 Winter St
WALTHAM   MA   02451-1424

Phone: +1617.5514000

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.

SPONSORED STORIES